Pasar al contenido principal

Investigación y educación

Enviado por remote_content el

Head-to-head comparison of CLSI, EUCAST, Etest and VITEK®2 results for Candida auris susceptibility testing. Int J Antimicrob Agents.

Investigación y Educación

Alvarez-Moreno CA. 25/02/2022

ABSTRACT
The susceptibility of 31 Candida auris clinical isolates was evaluated by four methods, namely the microdilution reference method according to Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines as well as Etest and VITEK®2. Essential agreement between the two reference methods was 90%. Etest showed a better overall agreement with the reference methods (94% and 81% for CLSI and EUCAST, respectively) than VITEK®2 (70% and 72%, respectively). Discrepancies were found for fluconazole (FLC) and amphotericin B. Considering categorical agreement (CDC tentative breakpoints), the majority of isolates were considered FLC-resistant (93.6% and 80.6% by CLSI and EUCAST, respectively). Furthermore, all isolates were considered susceptible to echinocandins by all methods. Susceptibility results should be interpreted with care if the VITEK®2 system is used to guide therapeutic decisions for C. auris infections.

Read full article

Artículos que te pueden interesar

Enfermedades infecciosas

Imaging manifestations of pulmonary melioidosis: A case series. Radiologia (Engl Ed).

Leer más

Enfermedades infecciosas

Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: a pragmatic, open-label randomized trial. EClinicalMedicine.

Leer más

Enfermedades infecciosas

Implications of Antibiotic Use During the COVID-19 Pandemic: The Example of Associated Antimicrobial Resistance in Latin America. Antibiotics

Leer más